treatment beyond progression (TBP) gets

[Olga]

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747319/
from (5):
A global rate of 21% patients received TBP for more than 6 weeks and 7% of the intention to treat population had a ≥30% tumor shrinkage versus baseline after TBP [55]. Moreover, a subgroup of patients treated with nivolumab in the CheckMate 025 trial achieved a benefit from TBP, showing a tumor reduction after the first PD [56].
so either the scanning was wrong or there was a response after the initial true progression.
we are using data from RCC trials as this is the closest cancer by typical clinical history and by the morphology to ASPS

[D.ap]

Olga
Great article .
I couldn’t agree with you more that a look see at the 3rd dimension , is truly an important clue to assess the true response to these ICIs success and or failures .

Also to utilize all means available( ctdna circulating tumor DNA, biomarkers and follow up scans ) to check pseudo verses progressive disease , when taking a patient off ICIs.

These earlier statistics certainly gave us the beginning picture to begin to unravel a complex set of events.